The Art of Saying No - TDOC: Teladoc Health Inc

The Telemedicine Giant Losing Its Way

“The difference between successful people and really successful people is that really successful people say no to almost everything.” — Warren Buffett

Introduction: The Power of Subtraction

In the autumn of 1995, Steve Jobs returned to Apple and did something counterintuitive: he killed 70% of Apple’s products. Not because they were bad, but because they distracted from what mattered. This is the central paradox of value creation—the power lies not in what you do, but in what you refuse to do.

Warren Buffett keeps a list of companies he’s studied and rejected. Charlie Munger famously said his success came from “knowing the edge of my circle of competence.” Peter Lynch turned down hundreds of stocks for every one he bought. These aren’t stories about missing opportunities; they’re stories about the disciplined pursuit of only the best opportunities.

Sometimes, the companies we look at are perfectly fine companies at the wrong time or wrong price. A few are fascinating turnarounds that need more time. But all of them failed to answer three brutally simple questions satisfactorily:

1. How many birds are in the bush? (What’s the magnitude of return if the thesis works?)

2. How sure are you? (What’s the probability the thesis actualizes?)

3. How fast till you get them out? (What’s the realistic time horizon?)

For a LEAPs strategy—buying long-dated call options 12-24 months out—I need high conviction on all three. If any answer is unsatisfactory, the idea gets rejected. Period.

What follows is a detailed forensic examination of each rejection, complete with financial analysis, probability assessments, and the specific mechanical failures that killed each thesis. Think of it as a masterclass in what Charlie Munger calls “the psychology of misjudgment”—except here, we catch ourselves before the mistake.

Let’s begin.

---

TDOC: The Telemedicine Giant Losing Its Way

Date Analyzed: December 2, 2025
Current Price: ~$7.23 | Market Cap: ~$1.29B

The Pandemic Winner That Couldn’t Sustain

Teladoc Health was the poster child for pandemic-era investing. Stuck at home? Don’t want to visit a doctor’s office? Video call your physician! The stock went from $75 (pre-pandemic) to $308 (February 2021)—a 4x gain in under a year.

Today it trades at $7.23. That’s a 98% decline from the peak.

The Business Segments

1. Integrated Care (~60% of revenue)

• Virtual primary care

• Chronic condition management (acquired Livongo for diabetes/hypertension)

• Specialist consultations

• Preventative care (acquired Catapult Health)

2. BetterHelp (~40% of revenue)

• Direct-to-consumer mental health

• Therapy via video/phone/text

• Psychiatry services

The Financial Performance Deterioration

Q4 2024 (February 26, 2025):

• Revenue: $640.5M (vs. $660.5M year-ago, -3% decline)

• Loss Per Share: -$0.28 (vs. -$0.24 expected)

• Adjusted EBITDA: $74.8M (-35% year-over-year)

Integrated Care Segment:

• Adjusted EBITDA: $53.2M (-5% YoY)

BetterHelp Segment:

• Adjusted EBITDA: $21.7M (-63% YoY!)

The BetterHelp Collapse

BetterHelp, which drove much of Teladoc’s pandemic growth, is imploding:

• Revenue declining

• Margins compressing

• User churn increasing

Why?

1. Insurance Competition: Consumers shifting from cash-pay therapy (BetterHelp’s model) to insurance-covered therapy (traditional providers)

2. Advertising Costs: BetterHelp spends heavily on marketing. As customer acquisition costs rise and lifetime value falls, unit economics break down.

3. Quality Concerns: BetterHelp has faced criticism over therapist vetting and session quality. When you’re competing on convenience, quality concerns are fatal.

4. Goodwill Impairments: The market is telling you something when a company takes:

   • $790 million goodwill write-down (Q2 2024)

   • $59 million impairment (Q1 2025)

Those are non-cash charges, but they represent management admitting “we overpaid for acquisitions and they’re not worth what we thought.”

The Guidance Withdrawal

October 29, 2025: Teladoc narrowed guidance ranges

Previous Guidance:

• Net loss per share: ($1.35) to ($1.00)

• Revenue: $2.501B to $2.548B

Revised Guidance:

• Net loss per share: ($1.25) to ($1.10)

• Revenue: $2.51B to $2.53B

This looks like a narrowing, not a withdrawal. But the market viewed the lower end of revenue guidance as confirmation of demand problems.

Q1 2026 Guidance (May 2025):

• Revenue: $608M to $629M (vs. $632.9M expected)

• Adjusted EBITDA: $47M to $59M

Missing expectations and guiding down is never bullish.

The Insider Selling Bonanza

This is where my analysis got damning:

Chief Accounting Officer:

• Acquired shares via RSU allocation

• Sold ~60% immediately

Multiple Directors:

• Received RSU shares

• Sold significant portions immediately upon vesting

CEO:

• Received RSUs

• Disposed of significant portion

Pattern Recognition:

When insiders receive stock as compensation and immediately sell most of it, they’re telling you:

1. They don’t believe in the current valuation (or)

2. They need liquidity (unlikely for high-paid executives) (or)

3. They know something you don’t (most likely)

My Analysis: “Massive insider sales of RSUs, with executives disposing of 60-80% of allocated shares immediately upon vesting.”

This isn’t “normal tax planning.” Executives typically hold 50-70% of RSU grants as a vote of confidence. Selling 60-80% immediately is a vote of no confidence.

The Competitive Moat Erosion

Original Teladoc Moat (2010-2020):

1. First-mover advantage in telehealth

2. Network effects (more doctors → more patients → more doctors)

3. Employer/insurance contracts (B2B2C distribution)

4. Technology platform (proprietary)

Moat Erosion (2020-2025):

1. Competition Exploded:

   • Amazon Health: Deep pockets, existing Prime membership, logistics advantage

   • CVS/Aetna: Integrated insurance + pharmacy + telehealth

   • Walgreens/VillageMD: Physical + virtual hybrid

   • Mayo Clinic/Cleveland Clinic: Premium brand telehealth

   • Hundreds of startups: Better UX, better pricing

2. Regulatory Changes: Pandemic-era telehealth waivers expired, reducing reimbursement and convenience

3. Patient Preferences: Post-pandemic, people returned to in-person care

4. Technology Commoditization: Video calling is trivial now. Zoom, Teams, Google Meet all have healthcare-compliant versions. The technology moat evaporated.

The Valuation Question

Liquidation Value:

• Current Assets: $1.6 billion

• Total Liabilities: $2.0 billion

• Net: -$400 million (negative!)

So liquidation value is zero. Equity holders get nothing if they shut down.

Market Cap: $1.29 billion

So the market is pricing in $1.29B of going-concern value above liquidation.

Is That Justified?

Only if you believe:

1. BetterHelp can stabilize (currently declining)

2. Integrated Care can grow (currently flat)

3. Profitability can be achieved (currently losing money)

4. Competition won’t intensify (it’s intensifying)

I’m not confident in any of these.

The Expected Value Calculation

Bull Case (20% probability):

• BetterHelp stabilizes at lower but sustainable level

• Integrated Care grows mid-single-digits

• Company achieves breakeven, then profitability

• Stock reaches $12-15

• Return: 1.8x

Base Case (50% probability):

• Slow decline continues

• Cash burn persists

• Market cap erodes to $700-900M

• Stock falls to $4-5

• Return: 0.65x

Bear Case (30% probability):

• BetterHelp continues collapsing

• Integrated Care growth stalls

• Company forced to raise capital dilutively or sell assets

• Stock falls to $2-3

• Return: 0.30x

Expected Value: (0.20 × 1.8) + (0.50 × 0.65) + (0.30 × 0.30) = 0.80x

Expected loss of 20%.

Birds in the Bush: 1.8x absolute best case
Probability of Success: 20%
Time Horizon: 3-4 years minimum

The Lesson: Pandemic Winners Rarely Stay Winners

The pandemic created artificial demand for:

• Telemedicine (Teladoc)

• Home fitness (Peloton)

• Video conferencing (Zoom)

• Food delivery (DoorDash, Uber Eats at inflated prices)

• Remote work tools (Asana, Monday.com)

• E-commerce (Shopify)

When the world reopened, mean reversion happened violently.

The Pattern:

1. 2020-2021: Massive growth as behavior shifts temporarily

2. 2021-2022: Peak optimism, stocks hit all-time highs

3. 2022-2023: Reality sets in, growth slows, stocks crater

4. 2024-2025: New normal emerges, much lower than pandemic peak

Teladoc Timeline:

• 2019: $9.30 stock price

• Feb 2021: $308 (33x gain!)

• Dec 2025: $7.23 (98% decline from peak, 22% below pre-pandemic)

The Question: If Teladoc is trading below its pre-pandemic price, doesn’t that mean it’s cheap?

The Answer: No. Because:

1. Debt increased: Balance sheet worse than pre-pandemic

2. Competitive intensity higher: More competitors than 2019

3. Growth rate lower: Pandemic pulled forward years of demand

4. Profitability worse: Still losing money despite $2.5B revenue scale

The company is structurally worse than pre-pandemic, despite being larger.

Verdict: Rejection. The competitive moat has eroded, insider selling signals low confidence, and the path to profitability is unclear. At $7.23, the stock prices in ~20% probability of success—and I think that’s optimistic. Fair value is probably $4-5, implying perhaps 30-45% further downside.

---

Learnings To Stick To

1. Dilution is Value Destruction

It doesn’t matter if a company has $200 million in cash if they’re issuing $300 million in equity at pennies on the dollar. Per-share value is what matters, not absolute value.

2. Debt is Fragility

Interest coverage below 3x means one bad year could trigger covenant breaches. Below 2x is playing with fire. Below 1.5x is suicidal.

3. Insiders Always Know First

When CEOs, CFOs, and directors sell 60-80% of vested RSUs immediately, they’re voting with their wallets. Listen.

4. Business Models Matter More Than Operations

You can’t cost-cut your way to success if the fundamental value proposition is obsolete.

5. Timing Is Everything (For Options)

e.g. MDU Resources and Krispy Kreme might be great investments... in 2027. But for LEAPs expiring in 2026, the timeline doesn’t work.

6. Regulatory Red Flags Are Never False Alarms

When annual reports are encrypted, when revenue collapses without explanation, when short sellers publish specific fraud allegations—walk away. The risk isn’t worth the reward.

7. Pandemic Winners Are Usually Losers

Mean reversion is brutal. Companies that benefited from temporary behavioral shifts rarely maintain those gains.

The Philosophy of “No”

Charlie Munger said: “The art of being wise is the art of knowing what to overlook.”

In investing, success comes from:

1. Saying yes to the right opportunities (important)

2. Saying no to the wrong opportunities (more important)

3. Saying no to marginal opportunities (most important)

This article is about #3. None of these companies were obviously terrible (well, maybe CHR and WIMI). Most had legitimate businesses, real assets, and plausible turnaround stories.

But “plausible” isn’t “probable.”
And “interesting” isn’t “investable.”

The Buffett-Munger Standard

Before investing, ask:

1. Do I understand this business? (Circle of competence)

2. Does it have a sustainable competitive advantage (Moat)/ does it have a legitimate working business model (for LEAPs)?

3. Is management trustworthy and aligned? (Stewardship)

4. Is the price attractive relative to intrinsic value? (Margin of safety)

5. What could go wrong? (Risk analysis)

For LEAPs specifically, add: 6. Will value be realized in 12-24 months? (Timing) 7. Is the expected return 2x+ to compensate for time decay? (Return threshold)

If the answer to ANY of these is “no” or “uncertain,” walk away.

The Opportunity Cost Mindset

Every dollar invested in these marginal opportunities is a dollar not available for exceptional opportunities.

Your capital is finite. Your attention is finite. Your time is finite.

Protect all three zealously.

When I reject companies, I’m not losing opportunities—I was preserving capital and attention for better opportunities yet to come.

In investing, a 0% success rate at finding investments can be a 100% success rate at avoiding disasters.